Cirrhosis and autoimmune liver disease: Current understanding

Rodrigo Liberal, Charlotte R Grant

Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) constitute the classic autoimmune liver diseases (AILDs). While AIH target the hepatocytes, in PBC and PSC the targets of the autoimmune attack are the biliary epithelial cells. Persistent liver injury, associated with chronic AILD, leads to un-resolving inflammation, cell proliferation and the deposition of extracellular matrix proteins by hepatic stellate cells and portal myofibroblasts. Liver cirrhosis, and the resultant loss of normal liver function, inevitably ensues. Patients with cirrhosis have higher risks or morbidity and mortality, and that in the decompensated phase, complications of portal hypertension and/or liver dysfunction lead to rapid deterioration. Accurate diagnosis and monitoring of cirrhosis is, therefore of utmost importance. Liver biopsy is currently the gold standard technique, but highly promising non-invasive methodology is under development. Liver transplantation (LT) is an effective therapeutic option for the management of end-stage liver disease secondary to AIH, PBC and PSC. LT is indicated for AILD patients who have progressed to end-stage chronic liver disease or developed intractable symptoms or hepatic malignancy; in addition, LT may also be indicated for patients presenting with acute liver disease due to AIH who do not respond to steroids.

Key words: Hepatic fibrosis; Cirrhosis; Myofibroblasts; Primary biliary cirrhosis; Primary sclerosing cholangitis; Autoimmune hepatitis; Liver transplantation

Core tip: In chronic liver disease, including autoimmune liver diseases, perpetual liver injury leads to persistent inflammation, cell proliferation and the deposition of extracellular matrix proteins. If left untreated, this process eventually leads to the development of liver cirrhosis, characterised by the presence of fibrosis and nodular regeneration. Liver biopsy is currently the gold standard technique, but highly promising non-invasive methodology is under development.
INTRODUCTION
Liver disorders with probable autoimmune aetiology include autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Each disease complies with, to varying extents, a proposed "multiple hit hypothesis" accounting for autoimmunity development, in which interacting environmental, infectious, genetic, epigenetic and immunological factors account for the loss of tolerance to self-constituents[1]. While AIH target the hepatocytes, in PBC and PSC the targets of the autoimmune attack are the biliary epithelial cells. Each of the autoimmune liver diseases (AILDs) is associated with distinct epidemiological and clinical characteristics. However, overlap syndromes, characterised by the coexistence of features of more than one AILD, are increasingly being recognised[2].

AILDS

PBC
PBC is a cholestatic autoimmune liver disease characterised by progressive destruction of the small and intermediate-sized bile ducts[3]. The histologic picture of PBC involves non-suppurative cholangitis with destruction of the biliary epithelium and portal infiltration of inflammatory cells. PBC also presents with biochemical evidence of cholestasis. PBC has pronounced female preponderance and a strong tendency to present in middle age[3]. Epidemiological characteristics of PBC are outlined in Table 1.

High titre positivity for serum anti-mitochondrial autoantibodies (AMAs) is pathognomonic for PBC, being detected in up to 95% of patients[3-5]. Moreover, asymptomatic people with AMA-positivity eventually progress to disease development[6]. AMAs target lipoylated domains of the 2-oxoacid dehydrogenase complex[3-5], with the immunodominant epitope belonging to the E2 components of the pyruvate dehydrogenase complex[3-5,7]. PBC-specific anti-nuclear autoantibodies (ANAs), with a characteristic "multiple nuclear dot" or "nuclear membrane" pattern, are found in 25%-40% of patients[8].

There is mounting evidence that the development of PBC can be accounted for by a proposed "multiple hit" hypothesis for the development of autoimmune (Figure 1). The molecular mimicry hypothesis postulates that microorganisms with epitopes that are structurally similar to self-components trigger an immune response with interspecies promiscuity. Several potential infectious triggers have been proposed[9] including *Escherichia coli*[10-14] and *Nosphingobium aromaticivorans*[15-17].

Numerous lines of evidence demonstrate that genetic factors alter susceptibility to PBC development. Female relatives of patients are at increased risk of developing PBC, and there is a high concordance rate between monozygotic twins[18]. Strong genetic associations lying within the MHC, for example HLA-DR8 in Europe and North America, have consistently been reported[19,20]. Genome wide association studies (GWAS) have revealed non-MHC gene associations that could be related to abnormal immune activation, including *IL12A*, *IL12RB2*, STAT4 and CTLA4[21-23].

Ursodeoxycholic acid (UDCA) is the standard treatment for PBC, improving both biochemical and histological indicators of disease activity and elongating transplant-free survival time in a significant proportion of patients[24,25].

PSC
PSC is a chronic inflammatory disease of the biliary epithelium, characterised by progressive bile duct destruction. The small, medium and large bile ducts are affected by obliterative concentric fibrosis which leads to the development of biliary strictures[26]. In contrast to the other AILDs, PSC affects males more commonly than females[27]. The median age of onset is approximately 41 years of age[27] (Table 1).

The most common biochemical abnormality in PSC patients is elevated serum alkaline phosphatase (AP)[28]. The most reliable diagnostic tool is cholangiography, which enables visualisation of characteristic multifocal strictures within the intra- and extra-hepatic bile ducts[29]. Concomitant inflammatory bowel disease (IBD), most frequently ulcerative colitis, is found in up to 80% of patients[28,30].

As with the other AILDs, the aetiology of PSC remains unknown but it is likely to follow the proposed multiple hit hypothesis (Figure 1), resulting from interplay between numerous genetic and environmental factors. The strong link with IBD has led to the emergence of the gut/lymphocyte homing hypothesis, which postulates that memory lymphocytes primed in the gut-associated lymphoid tissue, and therefore expressing the gut/cognate chemokine for CCR9, CCL25, both usually restricted to the gut[31], migrate from the gastrointestinal tract to the liver[32]. Importantly, the ligand for α4β7, MAdCAM-1, and the cognate chemokine for CCR9, CCL25, both usually restricted to the gut[33], are aberrantly expressed in the portal vein endothelium and sinusoidal endothelium respectively in PSC patients. Moreover, approximately 20% of liver-infiltrating T cells express α4β7 and CCR9, and have an effector memory phenotype[34,35]. The "leaky gut hypothesis", on the other hand, involves direct translocation of intestinal flora via the portal vein[28]. Although direct evidence of this phenomenon is lacking[36], future studies investigating the influence of the gut microbiota on PSC development/progression are warranted.

Similarly to the other AILDs, the strongest PSC genetic associations lie within HLA gene. In GWAS, the strongest association signals have been found near HLA-B[37-39]. There are, however, also believed to be HLA class II
The observation that the hepatitis C virus shares high sequence homology with the auto-antigenic target of anti-LKM-1 autoantibodies, cytochrome P450-2D6, has led to the suggestion that molecular mimicry could trigger AIH development in a genetically predisposed host\(^{43,44}\). Other potential triggers for AIH include the hepatitis B virus, cytomegalovirus, and the herpes simplex virus\(^{43}\).

Genetic associations affecting susceptibility to disease development, response to therapy and prognosis have been reported\(^{45}\). The most significant genetic associations lie within the MHC, at the HLA-DRB1 locus. Susceptibility to AIH type-1 is linked to alleles encoding the HLA-DR3 and DR4 molecules\(^{46}\), while AIH-2 susceptibility and severity have been linked to alleles encoding the HLA-DR3 and DR7 molecules\(^{47}\). Susceptibility to AIH has also been linked to polymorphisms in genes located outside the MHC, including \(\text{CTLA-4}\)\(^{48}\), \(\text{TNF-}\alpha\)\(^{49}\) and \(\text{Fas}\)\(^{50}\).

With the standard treatment regimen for AIH - prednisolone, with or without the addition of azathioprine - up to 80% of AIH patients are able to reach remission\(^{51}\).

### Overlap syndromes

It is not uncommon for patients to present with features characteristic of AIH and either PSC or PBC. Because standardised and validated diagnostic criteria are lacking, these “overlap syndromes” remain ill defined. PBC/AIH overlap is present in some 10% of AIH or PBC patients\(^{52,53}\), and the most commonly used method for diagnosis is the presence of two of the following features of AIH in conjunction with two of the following features of PBC. The AIH features are: (1) ALT at least 5 times the upper limit of normal (ULN); (2) SMA positivity or IgG level of at least 2 times ULN; and (3) liver histology showing moderate or severe periportal or periseptal inflammation. The PBC criteria are: (1) AP at least twice ULN or gamma glutamyl transferase above 5 times ULN; (2) AMA positivity; and (3) bile duct lesions on liver biopsy\(^{52,54,55}\). PBC/AIH overlap is now believed to represent a significant proportion of patients with AILD\(^{56,57}\).

The characteristics of AIH/PSC overlap are the classical features of AIH-1 - positivity for ANA and/or SMA, high IgG levels and interface hepatitis on biopsy - in addition to biochemical evidence of cholestasis, frequent

---

**Table 1 Epidemiological characteristics associated with the three autoimmune liver diseases**

|                      | PBC                                 | PSC                                 | AIH          |
|----------------------|-------------------------------------|-------------------------------------|--------------|
| Female/male ratio    | 10/1                                | 1/2                                 | 4/1          |
| Average age at presentation | 50                                  | 41                                  | Childhood/adolescence and approximately 40 |
| Incidence            | 0.33-5.8/100000                     | 0.13-1.7/100000                     | 0.08-3/100000 |
| Prevalence           | 1.91-40.2/100000                    | 0.16-2.4/100000                     | 11.6-35.9/100000 |
| Risk within family   | 1° degree relative incidence 4%-6%  | Unknown                             | Unknown      |
| Concordance in monozygotic twins | 60%                                | Only case reports                    | Only case reports |
| Note                 | AMA positivity                       | Frequent association with IBD       | Frequent association with IBD |
|                      |                                     | Positivity for ANA and or SMA       | Increased risk of hepatobiliary/colorectal malignancies |

AIH: Autoimmune hepatitis; AMA: Anti-mitochondrial autoantibodies; ANA: Anti-nuclear autoantibody; IBD: Inflammatory bowel disease; LKM: Liver kidney microsomal; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis; SMA: Smooth muscle autoantibody.

---

**Figure 1  “Multiple hit hypothesis” accounting for the development of autoimmune disease**. Interplay between immunological, genetic, epigenetic and environmental factors is thought to account for the loss of tolerance to self constituents in AILD. AILD: Autoimmune liver disease.
Liver damage in the context of the cholestatic AILDs. Liver damage may be caused by inflammation and liver cell injury, leading to the activation and differentiation of quiescent hepatic stellate cells (HSC) and portal fibroblasts (PF) into activated myofibroblasts. These proliferative, pro-inflammatory and pro-fibrogenic myofibroblasts increase collagen synthesis and deposit extracellular matrix proteins (ECM), leading to the development of fibrous scar tissue. Cirrhosis, characterised by significant fibrosis and nodular regeneration, eventually ensues, with the resultant loss of liver function and eventually liver failure.

![Figure 2 Development of fibrosis and cirrhosis in autoimmune liver disease](image)

In chronic liver disease, including AILD, perpetual liver injury leads to persistent inflammation, cell proliferation and the deposition of extracellular matrix proteins. If left untreated, this process eventually leads to the development of liver cirrhosis, characterised by nodular regeneration diffuse nodular regeneration surrounded by fibrotic septa with consequent extinction of the parenchyma, together leading to distortion of hepatic vascular architecture. Loss of normal liver function inevitably ensues (Figure 2).

Hepatic stellate cells, found in the space of Dissé, have long been believed to be the main contributors to liver fibrosis. Liver damage induces hepatic stellate cells to differentiate into proliferative and contractile myofibroblasts, with a pro-inflammatory and fibrogenic phenotype. Portal fibroblasts, located in the connective tissue of the portal triad are another source of myofibroblasts. These are of particular importance in the context of the cholestatic AILDs. Liver damage leads to the myofibroblastic differentiation of quiescent portal fibroblasts, a process which can be enhanced in these conditions by the cholangiocytes themselves. When cholangiocytes become “reactive”, they proliferate and express co-stimulatory molecules, chemokines and pro-fibrogenic molecules, therefore further promoting fibrogenesis. Bile acids, elevated as a consequence of cholestasis, could also perpetuate fibrogenesis indirectly by damaging hepatocytes, or by directly targeting myofibroblasts.

It has also been suggested that hepatic myofibroblasts could arise from hepatocytes or cholangiocytes via epithelial-mesenchymal transition, whereby polarised epithelial cells undergo phenotypic transformation in response to microenvironmental cues. There are reports that hepatic epithelial cells can acquire some of the phenotypic characteristics of myofibroblastic cells in vitro. Co-expression of epithelial and fibroblastic cell markers has also been described in human tissue sections. However, partly because these cell “markers” inadequately define both the epithelial and fibroblastic populations, conclusive evidence of epithelial-mesenchymal transition has been hard to come by. Furthermore, lineage tracing studies, using Cre/lox recombination, have failed to find evidence of liver epithelial cell-mesenchymal transition in murine models of bile-duct ligation or hepatitis induced by carbon tetrachloride (CCL₄) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine.

**FIBROSIS: KEY PLAYERS**

In chronic liver disease, including AILD, perpetual liver injury leads to persistent inflammation, cell proliferation and the deposition of extracellular matrix proteins. If left untreated, this process eventually leads to the development of liver cirrhosis, characterised by nodular regeneration diffuse nodular regeneration surrounded by fibrotic septa with consequent extinction of the parenchyma, together leading to distortion of hepatic vascular architecture. Loss of normal liver function inevitably ensues (Figure 2).

Hepatic stellate cells, found in the space of Dissé, have long been believed to be the main contributors to liver fibrosis. Liver damage induces hepatic stellate cells to differentiate into proliferative and contractile myofibroblasts, with a pro-inflammatory and fibrogenic phenotype. Portal fibroblasts, located in the connective tissue of the portal triad are another source of myofibroblasts. These are of particular importance in the context of the cholestatic AILDs. Liver damage leads to the myofibroblastic differentiation of quiescent portal fibroblasts, a process which can be enhanced in these conditions by the cholangiocytes themselves. When cholangiocytes become “reactive”, they proliferate and express co-stimulatory molecules, chemokines and pro-fibrogenic molecules, therefore further promoting fibrogenesis. Bile acids, elevated as a consequence of cholestasis, could also perpetuate fibrogenesis indirectly by damaging hepatocytes, or by directly targeting myofibroblasts.

It has also been suggested that hepatic myofibroblasts could arise from hepatocytes or cholangiocytes via epithelial-mesenchymal transition, whereby polarised epithelial cells undergo phenotypic transformation in response to microenvironmental cues. There are reports that hepatic epithelial cells can acquire some of the phenotypic characteristics of myofibroblastic cells in vitro. Co-expression of epithelial and fibroblastic cell markers has also been described in human tissue sections. However, partly because these cell “markers” inadequately define both the epithelial and fibroblastic populations, conclusive evidence of epithelial-mesenchymal transition has been hard to come by. Furthermore, lineage tracing studies, using Cre/lox recombination, have failed to find evidence of liver epithelial cell-mesenchymal transition in murine models of bile-duct ligation or hepatitis induced by carbon tetrachloride (CCL₄) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine.

**NATURAL HISTORY OF CIRRHOSIS**

It is well known that, compared with pre-cirrhotic patients, patients with cirrhosis have higher risks or morbidity and mortality. Cirrhosis can be divided into a compensated phase, free of symptoms, and a decompensated phase, in which complications of portal hypertension and/or liver dysfunction lead to rapid deterioration. The two stages can be considered separate clinical entities according to the AASLD and EASL guidelines. Median survival time in the compensated phase is over 12 years, whereas survival in the decompensated phase drops to approximately 2 years. The decompensated phase is defined by the development of jaundice, ascites, variceal haemorrhage or encephalopathy. The compensated stage has been further divided into stage 1, consisting of patients lacking varices, and stage 2, characterised by the presence of varices in the absence or variceal bleeding. The decompensated stage has been split into stage 3, associated with ascites and a lack of variceal haemorrhage, and stage 4, comprising patients with variceal haemorrhage (with or without ascites). One year mortality rates of 1%, 3%, 20% and 57% respectively have been reported. In a recent study, however, Zipprich et al. (2012) failed to replicate entirely these reported values, finding that stage 3 and stage 4 patients had one year survival rates of approximately 20% and 18% respectively. The authors of this study cite recent advances in variceal haemorrhage therapy as a potential reason for this discrepancy and proposed modifications to the system of stratification. The newly defined...
stage 3 consists of patients with variceal haemorrhage but without ascites, while stage 4 is characterised by the presence of ascites (with or without variceal bleeding)[84].

The risk of progression from compensated to decompensated cirrhosis is approximately 31% in the first year of diagnosis and 5%-7% thereafter[86]. Because of the striking reduction in survival time in the decompensated state, it is important to identify patients at greatest risk of cirrhosis progression. Newly developed non-invasive techniques for fibrosis/cirrhosis assessment are currently being tested.

The Child-Pugh, and more recently developed Model of End-Stage Liver Disease (MELD) Scores are the most widely used methods by which prognosis is assessed in the context of end-stage liver disease. The Child-Pugh Score incorporates values between 1 and 3 for each of the following criteria: Degree of encephalopathy, presence of ascites, serum bilirubin and albumin levels and international normalised ratio (INR). The MELD score encompasses bilirubin, INR and creatinine levels[87]. MELD was initially developed for predicting survival following transhepatic portosystemic shunt, but is now used to accurately predict survival in the context of cirrhosis[88], list patients for transplant and allocate organs.

DIAGNOSING CIRRHOSIS
Liver biopsy is still the most accurate and widely used method by which cirrhosis can be diagnosed and staged. There are, however, notable disadvantages to this method of examination, including cost, risk of bleeding, and sampling error[89]. Non-invasive tests for both diagnosis and assessment of fibrosis/cirrhosis progression are becoming increasingly sought. Proposed tests include those using the results of routine liver-function examinations, such as the AST-to-platelet ratio index, as well as examinations to measure liver stiffness; FibroTest and transient elastography (TE; FibroScan)[90,91]. There are promising indications that non-invasive methods could be used in the context of AILD. In PBC, liver stiffness tests show high performance in diagnosing significant fibrosis, severe fibrosis and cirrhosis. Progression of liver stiffness has also been used as an accurate measure of overall prognosis in PBC[92-94]. The addition of serological markers to the liver stiffness score does not appear to improve test outcome[95]. In a study also involving both PBC and PSC patients, liver stiffness was also shown to correlate with progression of fibrosis and histological scores[96]. Using a cohort of 404 patients with varied liver diseases, including PBC, PSC and AIH, Malik et al[90] (2010) found that liver stiffness scores accurately identified patients with compensated cirrhosis. Although highly promising, these results, particularly in the context of AIH, need to be confirmed in larger cohorts of patients.

CIRRHOSIS IN AILD
Cirrhosis in PBC
PBC progresses through a number of stages: Preclinical, asymptomatic, symptomatic, and liver failure. The preclinical phase is symptom-free and is associated with AMA positivity in the absence of biochemical indications of liver disease[6,97]. Biochemical abnormalities eventually appear after a median time of 5.6 years (range, 1-20 years)[6], but this phase is not yet associated with the presence of symptoms. When symptoms eventually develop, they are most commonly fatigue and pruritus, and later varices, oedema or ascites.

Liver failure is characterised by the accelerated development of jaundice, and is associated with poor prognosis[98]. Mean survival for patients with a bilirubin of 2.0 mg/dL is 4 years, while for those with bilirubin of 6.0 mg/dL is only 2 years[99]. PBC prognosis has dramatically improved in the last 20 years thanks to earlier diagnosis and the introduction of UDCA as the mainstay of treatment[100-102].

UDCA slows fibrosis progression and delays cirrhosis development[101]. In clinical trials, UDCA treatment of PBC patients decreased the development of oesophageal varices and prolonged survival[102-105]. Cirrhosis does, however, still develop in UDCA-treated PBC patients[106]. Indeed, the development of cirrhosis under UDCA treatment is an independent predictor of negative outcome[101,107].

Histologically, PBC can be divided according to the presence of fibrosis/cirrhosis into four stages[107,109]. Stage one is characterised by portal inflammatory cell infiltrate, which, in stage two, invades the liver parenchyma. In stage three, bridging fibrosis, in which fibrotic septa extend from and link the portal tracts, can be seen. Stage four is characterised by progression to cirrhosis[6,109]. The development of cirrhosis does not occur uniformly throughout the liver, thus features of all four stages can occur simultaneously in a single biopsy specimen. Histological staging should depend upon the most advanced histological features[99].

Histological stages can predict survival of PBC patients[110]. In untreated PBC patients, the median time to the development of extensive fibrosis is 2 years. The probability of remaining in early stages after 4 years is 29%, whereas development of cirrhosis occurs in 50% of patients originally demonstrating histological evidence of interface hepatitis without fibrosis[111]. In two studies the proportion of patients developing liver failure during a follow-up time of 5 years was found to be 15%[112] and 25%[113]. The development of oesophageal varices, and the associated impact on survival, has been examined in a prospective study over the course of 5.6 years, which included 256 patients[114]. Twenty-eight percent of patients were cirrhotic. Nearly one-third of patients developed oesophageal varices, after which the 3-year survival was 59%. Survival after the first bleeding episode was 46%[114].

The introduction of UDCA as first line treatment for PBC patients has changed the natural history of the disease[25,100,115,116]. Indeed, the number of PBC patients requiring liver transplantation (LT) decreased by 20% in between 1996 and 2006[115]. Additionally, PBC has fallen in the ranking of the most common indications for LT
Cirrhosis in PSC
Typical symptoms of PSC, occurring in a variable number of patients include pruritus, abdominal pain, malaise, weight loss, and episodes of fever and chills\(^\text{117}\). About 50% of PSC patients will present symptomatically \(^\text{118,119}\). Similarly to PBC, PSC progresses through four histological stages \(^\text{120}\). In stage 1, which is known as the portal stage, changes are restricted to the portal tracts with features of mild hepatitis and cholangitis. Stage 2, known as the perportal stage, is characterised by extension of the lesion to include periportal fibrosis and occasionally interphase hepatitis. In this phase, the portal tracts are often notably enlarged. By stage 3, the septal stage, bridging fibrous septa have developed and the bile ducts have begun to degenerate and disappear. Stage 4 is characterised by cirrhosis\(^\text{120}\). The rate of progression through these stages has been investigated. Of PSC patients in the perportal stage, 42%, 66% and 93% progressed over 1, 2 and 5 years respectively. Of patients in the septal stage, 14%, 25% and 52% progressed over 1, 2 and 5 years respectively. In 15% of total observations, regression of histologic stage could be observed, highlighting the problem of sample variability when serial liver biopsies are used during the period of follow-up\(^\text{121}\).

PSC can present at later stages of disease development, with complications of cirrhosis and portal hypertension\(^\text{122}\). Similarly to other causes of cirrhosis, portal hypertension gradually develops in cirrhotic PSC patients\(^\text{119}\). In one study, 36% of 283 newly diagnosed PSC patients had varices\(^\text{122}\).

Cirrhosis in AIH
In a cohort of over 450 AIH patients, 30% had evidence of cirrhosis at diagnosis, with a further 10% developing cirrhosis during a median follow-up time of 7.2 years. The presence of cirrhosis at diagnosis correlated with negative outcome (LT or death)\(^\text{124}\). In another study, including 126 AIH patients, Feld et al\(^\text{125}\) (2005) reported that 33% of patients had histological evidence of cirrhosis at diagnosis. With the exception of platelet count, which was lower in patients with cirrhosis, laboratory parameters, patient demographics and AIH scores did not differ between cirrhotic and non-cirrhotic patients. A similar frequency of patients from each group were asymptomatic at diagnosis and an equivalent proportion had good response to treatment\(^\text{125}\). Importantly, similar response to treatment has also been reported elsewhere\(^\text{126}\). Feld et al\(^\text{125}\) (2005) also found, however, that the presence of cirrhosis significantly increased risk of progression to LT or death. Consistent with the above studies, Verma et al\(^\text{127}\) (2004) reported that 28% of AIH patients were cirrhotic at diagnosis. In this study, a further 20% of patients developed cirrhosis during 52 mo of follow-up. Again, cirrhosis was an independent predictor of poor outcome in this cohort\(^\text{127}\). On the other hand, studies in the adult\(^\text{126,128}\) and paediatric\(^\text{129}\) settings, of comparable size and methodology to those described above, have not found associations between the presence of cirrhosis at diagnosis and the likelihood of poor outcome.

In one study, patients diagnosed between the ages of 21 and 60 years of age were more likely to present with cirrhosis than those outside of this range. Male patients were also more likely to have cirrhosis compared to their female counterparts. Low serum albumin concentrations, prolonged INR and low platelet count were all more frequently associated with the cirrhotic group of AIH patients\(^\text{130}\).

There are indications that cirrhosis is more common among AIH type-1 patients compared to patients with type-2 AIH. In a paediatric study, 69% of ANA/SMA positive patients had evidence of “definite cirrhosis” on initial biopsy, whereas only 38% of patients positive for anti-LKM-1 were cirrhotic. On follow-up these values increased to 74% and 44% respectively\(^\text{131}\).

LT IN AILDs
LT is indicated for AILD patients who have progressed to end-stage chronic liver disease or developed intractable symptoms or hepatocellular carcinoma (HCC)\(^\text{132,133}\), in addition, LT may also be indicated for patients presenting with acute liver disease due to AIH who do not respond to steroids\(^\text{134}\). In total, AILDs accounts for almost one fourth of LTs performed in the United States and in Europe\(^\text{135}\).

LT for PBC
The indications for LT in PBC are, for the most part, identical to those in patients with end-stage chronic liver disease of other aetiology\(^\text{100,126}\). The majority of transplants occur due to end-stage chronic liver disease when the MELD score is higher than 16\(^\text{126}\). Other indications for LT include HCC, portopulmonary hypertension or hepato-pulmonary syndrome\(^\text{137}\). Other than this, few
PBC patients with non-cirrhotic portal hypertension associated with obliterator portal venopathy or nodular regenerative hyperplasia will benefit from transplant\(^{136}\). Finally, even when liver function is sufficient\(^{139}\), LT may be indicated if intractable symptoms, most notable refractory pruritus, are present\(^{137,140}\).

The immunosuppressive regimen most commonly used following LT is a combination of corticosteroids, which are withdrawn over a period of three months, a calcineurin inhibitor (CNI) and mycophenolate mofetil or azathioprine. This regimen has a very successful outcome\(^{136}\); with 1, 3 and 5 year patient survivals of 94%, 91% and 82% respectively, and graft survivals of 85%, 83% and 75% respectively\(^{141}\). Analysis of the UNOS database showed that PBC living donor transplant recipients had estimated 1, 3 and 5 year patient survivals of 93%, 90% and 86% and deceased donor transplant recipients had estimated survivals of 90%, 87% and 85% respectively. Estimated graft survivals at 1, 3 and 5 years for living donor LT was 86%, 81% and 77% respectively, and for deceased donor LT was 85%, 83% and 81% respectively\(^{142}\).

**LT for PSC**

Similarly to PBC, and other liver diseases associated with cirrhosis, LT is indicated in PSC patients with end-stage liver disease (i.e., with a MELD score above 16)\(^{143,144}\). HCC can occur in PSC patients with cirrhosis, and in this context, LT prioritisation follows the same rule as that for other cirrhotic patients with HCC\(^{137,145}\). In PSC, LT may also be indicated in patients with intractable pruritus or those with recurrent bacterial cholangitis, and limited stage cholangiocarcinoma\(^{118,322,145}\).

LT for PSC usually has good outcome\(^{130}\). In one report, the 1, 2 and 5 year actuarial survival rates for LT for PSC were 90%, 86% and 85%, and graft survivals were 82%, 77% and 72% respectively\(^{146}\). In a study from the Mayo Clinic comprising 150 transplanted PSC cases, similar patient survival at 1, 2, 5 and 10 years of 94%, 92%, 86% and 70%, and graft survival of 83%, 83%, 79% and 61% was reported\(^{147}\).

**LT for AIH**

Overall, AIH accounts for some 3% of paediatric and up to 6% of adult LTs\(^{40}\). The natural course of AIH is understood mostly thanks to the last placebo-controlled trials published 4 decades ago\(^{148-150}\). These reports demonstrated that, without treatment, AIH patients have poor survival with 40% of deaths within 6 mo from diagnosis. With treatment, 10-year survival rate of AIH patients is over 80%\(^{125,151}\).

LT is indicated for AIH patients presenting with acute liver failure who do not respond to steroids, for those patients with advanced cirrhosis and for those with HCC\(^{118,152}\). The immunosuppressive strategy most commonly adopted consists in the combination of prednisolone and a CNI\(^{153}\), leading to excellent outcome with 5 and 10 year patient survivals of 90% and 75%\(^{51}\), and 1 and 5 year graft survivals of 84% and 75%\(^{51,154}\).

**REFERENCES**

1. Bogdanos DP, Gershwin ME. What is new in primary biliary cirrhosis? Dig Dis 2012; 30 Suppl 1: 20-31 [PMID: 23075865 DOI: 10.1159/000341118]

2. Boberg KM, Chapman RW, Hirschfeld GM, Lobhe AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385 [PMID: 21067838 DOI: 10.1016/j.jhep.2010.09.002]

3. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273 [PMID: 16177252 DOI: 10.1056/NEJMra043898]

4. Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003; 7: 759-777 [PMID: 14594130 DOI: 10.1016/S1089-3261(03)00104-1]

5. Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011; 412: 502-512 [PMID: 21185272 DOI: 10.1016/j.cca.2010.12.019]

6. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996; 349: 1389-1402 [PMID: 8937278 DOI: 10.1016/S0140-6736(96)64410-5]

7. Van de Water J, Gershwin ME, Leung P, Ansari A, Coppel RL. The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydroxyaspartate acetyltransferase. J Exp Med 1988; 167: 1791-1799 [PMID: 2455013 DOI: 10.1084/jem.167.6.1791]

8. Hirschfeld GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8: 303-330 [PMID: 23347352 DOI: 10.1146/annurev-pathol-020712-164014]

9. Snyk DS, Rigopoulos EI, Bogdanos DP. Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What’s New? Curr Infect Dis Rep 2013; 15: 14-24 [PMID: 23188623 DOI: 10.1007/s11908-012-0304-2]

10. Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulos E, Montalto P, Davies ET, Burroughs AK, Vergani D. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40: 31-39 [PMID: 14672611 DOI: 10.1016/S0168-8278(03)00501-4]

11. Burroughs AK, Rosenstein U, Epstein O, Hamilton-Miller JM, Brunfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25: 133-137 [PMID: 6363217 DOI: 10.1136/gut.25.2.133]

12. Shigematsu H, Shimoda S, Nakamura M, Matsuhashi S, Nishimura Y, Sakamoto N, Ichiki Y, Niho Y, Gershwin ME, Ishibashi H. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology 2000; 32: 901-909 [PMID: 11050037 DOI: 10.1053/heap.2000.18714]

13. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, Lake J, Keeffe EB, Roche TE, Gershwin ME. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998; 102: 1831-1840 [PMID: 9819369 DOI: 10.1172/JCI4213]

14. Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushina T, Gershwin ME, Ishibashi H. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology 2000; 31: 1212-1216 [PMID: 10827144 DOI: 10.1053/heap.2000.8090]

15. Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, Todd JA, Peterson LB, Savage PB, Wills-Karp M, Ridgway WM, Wicker LS, Mattner J. Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity. J Immunol 2011; 187: 337-349 [PMID: 21613619 DOI: 10.4049/jimmunol.1003252]

16. Olafsson S, Gadjoisson H, Selmi C, Amano K, Invernizzi P, Podda
M, Gershwin ME. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis: findings on cholangiography and pancreatography. Radiology 1993; 190(3): 39-44 [PMID: 8412283 DOI: 10.1148/radiology.190.3.8412283]

Boonstra K, van Erpemus KJ, van Nieuwkerk KM, Drenth JP, Poen AC, Witteman BT, Tuymans HA, Beuers U, Ponsioen CY. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2270-2276 [PMID: 22407885 DOI: 10.1002/ibd.22938]

Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Förster R, Aagave WW. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-protective T cell homeostasis. J Exp Med 2005; 202: 1063-1073 [PMID: 16216890 DOI: 10.1084/jem.200511100]

Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013; 46: 97-111 [PMID: 23891169 DOI: 10.1016/j.jaut.2013.06.013]

Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110 [PMID: 9212736]

Grant AJ, Lalor PF, Hübser SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 1065-1072 [PMID: 11343233 DOI: 10.1053/jhep.2001.24231]

Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hübser SG, Briskin M, Salmon M, Adams DH. Hepatic endothelial CCL25 mediates the recruitment of CCR6+ gut-homing lymphocytes to the liver in sclerosing cholangitis. J Exp Med 2004; 200: 1515-1517 [PMID: 15557349 DOI: 10.1084/jem.20041053]

Pollheimer MJ, Hallibasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011; 25: 727-739 [PMID: 22117638 DOI: 10.1016/j.bpg.2011.10.009]

Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weißmüller TJ, Gottardt D, Rust C, Philippe E, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck C, Nofthnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeiren S, Beuers U, Manns MP, Schrumpf E, Böhm KG, Schreiber S. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-1111 [PMID: 19944697 DOI: 10.1053/j.gastro.2009.11.046]

Melum E, Franke A, Schramm C, Weißmüller TJ, Gotthardt DN, Offner FA, Juran BD, Laerdahl JK, Labi V, Björnsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Curbishley SM, Butcher EC, Kassam N, Mackay CR, Carmo I, Trivedi PJ, Jois SC, Thrush TR, Bähler J, Jansen H, Schramm C, Weißmüller TJ, Gottardt DN, Rust C, Philippe E, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck C, Vermeiren S, Beuers U, Illig T, Nofthnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeiren S, Beuers U, Manns MP, Schrumpf E, Böhm KG, Schreiber S. Genome-wide association analysis in primary sclerosing cholangitis. Am J Gastroenterol 2010; 105: 97-110 [PMID: 20308635 DOI: 10.1111/j.1572-0241.2009.02824.x]

Linard K. Usoxosidehydroxyacid for the treatment of primary biliary cirrhosis. N Engl J Med 2007; 357: 1524-1529 [PMID: 17928600 DOI: 10.1056/NEJMct074694]

Linard KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308 [PMID: 19555443 DOI: 10.1002/hep.22906]

Portmann B, Zen Y. Inflammatory disease of the bile ducts: sclerosing cholangitis: liver biopsy challenge and clinicopathological correlation. Histopathology 2012; 60: 236-248 [PMID: 21688470 DOI: 10.1111/j.1365-2559.2011.08353.x]

Molodecky NA, Karelhi M, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53: 1590-1599 [PMID: 21351115 DOI: 10.1002/hep.24247]

Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-1599 [PMID: 23810223 DOI: 10.1016/S0140-6736(13)60096-3]
Liberal R et al. Cirrhosis and autoimmune liver disease

Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Amodeo V, Acciaro K, Bogdanos DP, Choudhuri K, Ma Y, Mahmoud A, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic autoimmunity: a consensus statement from the committee for autoimmunity of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683 [PMID: 15464251 DOI: 10.1016/j.jhep.2004.08.002]

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23594]

Vergani D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver autoimmune serology: a consensus statement from the committee for autoimmunity of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683 [PMID: 15464251 DOI: 10.1016/j.jhep.2004.08.002]

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23594]

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23594]

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23594]

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23594]
Evolving consensus in portal hypertension. *Gastroenterology* 2005; 128: 1042-1055 [PMID: 15825085 DOI: 10.1010/j.gastro.2005.01.007]

Choi SS, Drieh AM. Epithelial-to-mesenchymal transitions in the liver. *Hepatology* 2009; 50: 2007-2013 [PMID: 19824076 DOI: 10.1002/hep.23196]

Diaz R, Kim JW, Hui JJ, Li Z, Swain GP, Fong KS, Csiszar M, Vizzutti F, Arena U, Marra F. Technology Insight: Biliary epithelial-mesenchymal transition in liver fibrosis in mice. *Hum Pathol* 2008; 39: 102-115 [PMID: 17900655 DOI: 10.1016/j.humpath.2007.05.021]

Robertson H, Kirby JA, Yip W, Jones DE, Burt AD. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. *Hepatology* 2007; 45: 977-981 [PMID: 17393507 DOI: 10.1002/hep.21624]

Chu AS, R. Improved survival after variceal bleeding in patients with primary biliary cirrhosis. *Lancet* 2010; 375: 1419-1420 [PMID: 20471845 DOI: 10.1016/S0140-6736(09)62195-4]

Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: Non-invasive assessment of liver fibrosis by biochemical scores and elastography. *Nat Clin Pract Gastroenterol Hepatol* 2008; 5: 95-106 [PMID: 18253138 DOI: 10.1038/nccpgasthep0125]

Corpechot C, Barrat F, Poujol-Robert A, Gauzaar F, Wendam D, Chazouilleres O, Poupon R. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. *Hepatology* 2012; 56: 198-208 [PMID: 22271046 DOI: 10.1002/hep.25590]

Floreani A, Cazzagon N, Martines D, Cavalleto L, Baldo V, Chemello L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. *Dig Liver Dis* 2011; 43: 887-892 [PMID: 21783442 DOI: 10.1016/j.dld.2011.06.011]

Friedrich-Rust M, Muller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Pouyart N, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Comparison of transient elastography, FibroScan, MRI, MR-spectroscopy, and serum markers. *J Clin Gastroenterol* 2010; 44: 58-65 [PMID: 19581812 DOI: 10.1097/MCG.0b013e3181a485d]

Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendam D, Chazouilleres O, De Ledinghen V, Duhameau D, Marcellin P, Beaugrand M, Poupon R. Assessment of liver fibrosis by transient elastography in patients with PBC and PSC. *Hepatology* 2006; 43: 1118-1124 [PMID: 16628644 DOI: 10.1002/hep.21151]

Malik R, Lai M, Sadq A, Farnan R, Mehta S, Nasser I, Chailly T, Schuppan D, Afidhal N. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. *J Gastroenterol Hepatol* 2010; 25: 1562-1568 [PMID: 20796156 DOI: 10.1111/j.1440-1746.2010.06371.x]

Mayo MJ. Natural history of primary biliary cirrhosis. *Clin Liver Dis* 2008; 12: 277-288 [PMID: 18456180 DOI: 10.1016/j.cld.2008.02.012]

Shapiro JM, Smith H, Schaffer F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. *Gut* 1979; 20: 137-140 [PMID: 428825]

Prince MJ, James OF. The epidemiology of primary biliary cirrhosis. *Clin Liver Dis* 2003; 7: 795-819 [PMID: 14594132]

Selmi C, Bouwls CL, Gerishin ME, Coppell RL. Primary biliary cirrhosis. *Lancet* 2011; 377: 1600-1609 [PMID: 21529926 DOI: 10.1016/S0140-6736(10)61965-4]

Corpechot C, Barrat F, Bahr A, Chrétién Y, Poupen RE, Poupen R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. *Gastroenterology* 2005; 128: 297-303 [PMID: 15685541]

Poupen RE, Lindor KD, Parés A, Chazouillères O, Poupen R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. *Hepatology* 2003; 39: 12-16 [PMID: 12821038]

Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. *Mayo Clin Proc* 1997; 72: 1137-1140 [PMID: 9413293 DOI: 10.1016/S0025-6156(96)36376-8]

Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival patients with primary biliary cirrhosis. *Gastroenterology* 1996; 110: 1515-1518 [PMID: 8613058]

Poupen RE, Balkau B, Eschwège E, Poupen R. A multicenter,
controlled trial of ursoflox for the treatment of primary biliary cirrhosis. UDC-A-PBC Study Group. N Engl J Med 1991; 324: 1548-1554 [PMID: 1674105 DOI: 10.1056/NEJM199105303242404]

106 Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDC-A-PBC Study Group. N Engl J Med 1994; 330: 1342-1347 [PMID: 8152446 DOI: 10.1056/NEJM199405123301903]

107 Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-658 [PMID: 11784998]

108 Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-112 [PMID: 1506090 DOI: 10.1007/BF00432479]

109 Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J 1983; 59 Suppl 4: 106-115 [PMID: 6359113]

110 Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1-7 [PMID: 6849717 DOI: 10.1056/NEJM198310063080101]

111 Locke GR, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996; 23: 52-56 [PMID: 8550048 DOI: 10.1002/hep.510230108]

112 Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 1313-1315 [PMID: 17900996 DOI: 10.1016/j.cgh.2007.07.015]

113 Christensen E, Neuberger J, Crove J, Portmann B, Williams R, Altman DG, Popper H, Doniach D, Ranek L, Tygstrup N. Azathioprine and prognosis in primary biliary cirrhosis. Gastroenterology 1986; 90: 508-509 [PMID: 3510149 DOI: 10.1016/0016-5085(86)90972-8]

114 Gores GJ, Wisniewski RH, Dickson ER, Zinnsmeister AR, Jorgensen RA. Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989; 96: 1552-1559 [PMID: 2785470]

115 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 1313-1315 [PMID: 17900996 DOI: 10.1016/j.cgh.2007.07.015]

116 Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102: 1799-1807 [PMID: 17459023 DOI: 10.1111/j.1572-0241.2007.01235.x]

117 Broome U, Olsson R, Lööf B, Bodemar G, Hultcrantz R, Danie­ssen A, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergqvist A, Wallerstedt S, Sandberg-Gertzin H, Hultcrantz R, Sangfelt P, Weiland O, Danielsson A. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1233-1240 [PMID: 18609163 DOI: 10.1080/00365520802130183]

118 Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62 [PMID: 15954109 DOI: 10.1002/hep.20732]

119 Ngu JH, Beechy K, Chapman BA, Burt MI, Barclay ML, Garry RB, Stedman CA. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010; 25: 1681-1686 [PMID: 20880179 DOI: 10.1111/j.1440-1746.2010.06384.x]

120 Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857 [PMID: 8608895]

121 Radhakrishnan KR, Alkhoury N, Worley S, Arrigain S, Hupertz V, Kay M, Yerian L, Wiffle R, Feldstein AE. Autoimmune hepatitis in children—impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis 2010; 42: 724-728 [PMID: 20163994 DOI: 10.1016/j.dld.2010.01.002]

122 Ng JH, Garry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study. Hepatology 2013; 57: 2399-2406 [PMID: 23539535 DOI: 10.1002/hep.26290]

123 Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCarty M, Mowat AP, Vergani D, Mieli-Vergani G. Autoimmune hepatitis in children—impact of cirrhosis at presentation on natural history and long-term outcome. J. Gastroenterol Hepatol 2011; 26: 541-547 [PMID: 2100495 DOI: 10.1111/j.1440-1746.2011.06308]

124 Ahmed A, Kearfe EB. Current indications and contraindications for liver transplantation. Clin Liver Dis 2007; 11: 227-247 [PMID: 17606204 DOI: 10.1016/j.cld.2007.04.008]

125 Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl 2013; 19: 1065-1077 [PMID: 23873751 DOI: 10.1002/lt.23704]

126 Kessler WR, Cummings OW, Eckart G, Chalasani N, Lumeng L, Kwo FY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-631 [PMID: 15224287]

127 Ilyas JA, O’Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011; 25: 765-782 [PMID: 22117641 DOI: 10.1016/j.bpg.2011.09.008]

128 Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol 2008; 14: 3388-3395 [PMID: 18528936 DOI: 10.3748/wjg.14.3388]

129 Freeman RB, Gish RG, Harper A, Davis GL, Vierling J, Liebelin L, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12: S12-S136 [PMID: 17007907 DOI: 10.1016/j.cgh.2007.07.015]
Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia andobliterative portal venopathy. *Am J Surg Pathol* 2006; 30: 1454-1461 [PMID: 17063088 DOI: 10.1097/01.pas.0000213286.65907.ca]

Milkiewicz P, Wunsch E, Elias E. Liver transplantation in chronic cholestatic conditions. *Front Biosci* (Landmark Ed) 2012; 17: 959-969 [PMID: 22201783 DOI: 10.2741/3966]

Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. *J Hepatol* 2003; 39: 142-148 [PMID: 12873808]

Garcia CE, Garcia RF, Gunson B, Christensen E, Neuberger J, McMaster P, Mirza DF. Analysis of marginal donor parameters in liver transplantation for primary biliary cirrhosis. *Exp Clin Transplant* 2004; 2: 183-188 [PMID: 15859926]

Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V, Maloo M, Ryan C, Marroquin C, Barry C, Ramaraju G, Maliakkal B, Orloff M. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases—an analysis of the UNOS database. *J Gastrointest Surg* 2010; 14: 1362-1369 [PMID: 20617395 DOI: 10.1007/s11605-010-1256-1]

Wiesner RH. Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. *Best Pract Res Clin Gastroenterol* 2001; 15: 667-680 [PMID: 11492975 DOI: 10.1053/bega.2001.0212]

Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. *Am J Transplant* 2006; 6: 1416-1421 [PMID: 16686765 DOI: 10.1111/j.1600-6143.2006.01321.x]

Leidenius M, Höckersted K, Broome U, Ericzon BG, Friman S, Olausson M, Schrumpf E. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. *J Hepatol* 2001; 34: 792-798 [PMID: 11451160]

Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, Martin P, Stribling RJ, Goldstein LL, Basuttil RW. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. *Ann Surg* 1997; 225: 472-481; discussion 481-483 [PMID: 9193175]

Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. *Hepatology* 1999; 30: 1121-1127 [PMID: 10534330 DOI: 10.1002/hep.510300501]

Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. *Q J Med* 1971; 40: 159-185 [PMID: 4933363 DOI: 10.1093/oxfordjournals.qjmed.a067264]

Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, Schoenfeld LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. *Gastroenterology* 1972; 63: 820-833 [PMID: 4538724]

Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. *Lancet* 1973; 1: 735-737 [PMID: 4121073 DOI: 10.1016/S0140-6736(73)92125-9]

Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. *J Clin Gastroenterol* 2002; 35: 75-81 [PMID: 12080231]

Reich DJ, Fiel I, Guarrera JV, Emre S, Guy SR, Schwartz ME, Miller CM, Shenier PA. Liver transplantation for autoimmune hepatitis. *Hepatology* 2000; 32: 693-700 [PMID: 11003612 DOI: 10.1053/jhep.2000.16666]

Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. *Clin Gastroenterol Hepatol* 2012; 10: 346-353 [PMID: 22056300 DOI: 10.1016/j.cgh.2011.10.028]

Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. *Clin Transpl* 2004: 315-329 [PMID: 16704160]
